EVP, Human Resources · Anika Therapeutics, Inc. (ANIK)

Thomas Finnerty

A named executive officer of Anika Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,143,787

Salary $353,505Stock awards $626,367Bonus $143,169

FY2019: $1,135,879

5th of 7 named executive officers at Anika Therapeutics by FY2020 total.

7 named officers on file for Anika Therapeutics, FY2020

Thomas Finnerty’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 6 equity grants, each cited to its filing
  • ANIK’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Anika Therapeutics’s whole pay program stands against its peers

  • Anika Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ANIK→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2021 (DEF 14A).

Free

Get Thomas Finnerty’s full pay file as a PDF — free

More than this page: up to 10 years of Thomas’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Thomas Finnerty compensation by year

Anika Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Anika Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020
Salary$44,423$330,000$341,550$353,505
Bonus$0$118,800$184,437$143,169
Stock awards$367,812$0$585,540$626,367
Option awards$301,451$285,831$0$0
Non-equity incentive$0$0$0$0
Pension and deferred compensation$0$0$0$0
All other$2,508$24,002$24,352$20,746
Total$716,194$758,633$1,135,879$1,143,787

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Anika Therapeutics, Inc. DEF 14A filed April 30, 2021, accession 0001171843-21-002976, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Anika Therapeutics, Inc. filed document, accession 0001171843-21-002976. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2021.

$716K
$759K
$1.1M
$1.1M
FY17
FY18
FY19
FY20
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU14,500$656,270—
PSU9,620$435,401—
Option4,786—$61.47

Per the Outstanding Equity Awards at Fiscal Year-End table in Anika Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Anika Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Cheryl BlanchardPresident and Chief Executive Officer$10,029,434
Michael LevitzEVP, Chief Financial Officer and Treasurer$1,857,960
David ColleranEVP, General Counsel and Secretary$1,705,616
Sylvia CheungChief Financial Officer, Treasurer and Assistant Secretary$1,308,534
Thomas Finnerty · this pageEVP, Human Resources$1,143,787
James LoeropEVP, Business Development and Strategic Planning$1,039,871
Joseph DarlingPresident and Chief Executive Officer$288,753

The full Anika Therapeutics compensation record

free company brief

This page is one person within Anika Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Anika Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Anika Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Thomas Finnerty's compensation dossier · One-time report. No refunds.